主页 > 医学前沿 >
【drug-news】骨质疏松药前景看好, 安进公司股票大
Amgen Shares Rise As Strong Osteoporosis Study Results Offset Weak 2008 Outlook
NEW YORK (AP) -- Shares of Amgen Inc. jumped Friday as investors brushed off a weak 2008 profit outlook and focused on the market potential for the biotechnology company's osteoporosis drug candidate.
Amgen shares rose $2.02, or 4.4 percent, to $48.14 Friday. The stock has traded between $43.93 and $75.01 over the last 52 weeks.
Late Thursday, the company said it met Wall Street's fourth-quarter profit expectations, but its 2008 forecast fell short of consensus estimates. Sales of its best-selling anemia drug Aranesp slipped by about 12 percent in 2007 on safety concerns and Wall Street is mixed on whether the drug's market potential has bottomed out.
But, analysts were pleased with results from a study showing the osteoporosis drug denosumab was 40 percent more effective than Merck's Fosamax in treating postmenopausal women. Wall Street had been concerned with the drug candidate's viability in the market after study data in December failed to impress.
The drug must show a benefit over other treatments because it will compete against generic versions of Fosamax. Analysts have said physicians would be less likely to switch patients taking a cheaper generic drug.
Oppenheimer & Co. analyst Bret Holley expects denosumab study results to further drive Amgen shares in the second half of 2008, after additional data is released.
Meanwhile, Aranesp remains the unknown factor for many analysts. Safety concerns prompted the Food and Drug Administration to revise Aranesp's warning label in 2007 while federal reimbursement levels were cut for the drug. Aranesp and Epogen, along with Johnson & Johnson's Procrit, treat anemia in patients undergoing chemotherapy treatment or with kidney failure. Amgen will meet with an FDA panel in March to discuss new studies on Aranesp.
Holley said Aranesp sales have nearly bottomed and there will likely be no further decline in 2008. She reaffirmed an "Outperform" rating with a $65 price target.
Lehman Brothers analyst Dr. Jim Birchenough reaffirmed a "Overweight" rating but cut his price target to $69 from $72 and said the company's guidance might ultimately prove to be conservative. A negative outcome from the FDA panel meeting will likely already be absorbed into the company's guidance range.
Meanwhile, Lazard Capital Markets analyst Joel Sendek is maintaining a more cautious "Hold" rating for Amgen ahead of the company's meeting with the FDA panel.
"We maintain our view that the upcoming events in 2008 could have a further negative impact on sales," Sendek said, in a note to investors. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 由于事情有变，不能翻译学习，请战友示范：）
据美联社报道:
Amgen Shares Rise As Strong Osteoporosis Study Results Offset Weak 2008 Outlook
NEW YORK (AP) -- Shares of Amgen Inc. jumped Friday as investors brushed off a weak 2008 profit outlook and focused on the market potential for the biotechnology company's osteoporosis drug candidate.
纽约—安进公司的股票周五上涨，投资者不顾2008年盈利低的前景，将注意力投注在生物技术公司生产的骨质疏松药物的潜在市场。
Amgen shares rose $2.02, or 4.4 percent, to $48.14 Friday. The stock has traded between $43.93 and $75.01 over the last 52 weeks.
安进的股票在周五上涨2.02美元达到48.14美元，上涨了4.4%。过去的52周里，股票在43.93和75.01美元内交易。
Late Thursday, the company said it met Wall Street's fourth-quarter profit expectations, but its 2008 forecast fell short of consensus estimates. Sales of its best-selling anemia drug Aranesp slipped by about 12 percent in 2007 on safety concerns and Wall Street is mixed on whether the drug's market potential has bottomed out.
上周四，公司表示预期获得华尔街1/4的利润，但是2008年的预测没有达成共识。畅销的治疗贫血的Aranesp由于安全性问题，销售在2007年下降了12%，华尔街也困惑是否这个药物的潜在市场已经降至最小。
But, analysts were pleased with results from a study showing the osteoporosis drug denosumab was 40 percent more effective than Merck's Fosamax in treating postmenopausal women. Wall Street had been concerned with the drug candidate's viability in the market after study data in December failed to impress.
但是，有研究表明安进生产的骨质疏松药物denosumab比默克生产的Fosamax在绝经后的女性治疗中，有效性提高了40%，分析学家对这个研究带来的结果表示满意。华尔街已经开始关心这个药物在12月份的研究数据影响力不够的情况下的生存力。
The drug must show a benefit over other treatments because it will compete against generic versions of Fosamax. Analysts have said physicians would be less likely to switch patients taking a cheaper generic drug.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-06 17:16
医学,生命科学网